Published in Cancer on April 01, 2008
Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood (2010) 1.76
Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics (2012) 1.72
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem (2011) 1.46
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer (2010) 1.22
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer (2008) 1.16
Tissue microarrays: one size does not fit all. Diagn Pathol (2010) 1.10
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer (2008) 1.05
From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer (2009) 1.03
Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 0.96
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma. J Neuropathol Exp Neurol (2013) 0.89
The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. Korean J Urol (2011) 0.86
Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett (2013) 0.84
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget (2016) 0.83
Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma. Oncol Lett (2014) 0.82
Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res (2010) 0.82
Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression. PLoS One (2015) 0.81
Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases. Am J Cancer Res (2015) 0.80
The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. Elife (2016) 0.79
Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa. Int J Clin Exp Pathol (2014) 0.79
IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma. Lung (2015) 0.76
Increased Insulin mRNA Binding Protein-3 Expression Correlates with Vascular Enhancement of Renal Cell Carcinoma by Intravenous Contrast-CT and is Associated with Bone Metastasis. J Bone Oncol (2015) 0.76
Clinical implications of insulin-like growth factor II mRNA-binding protein 3 expression in non-small cell lung carcinoma. Oncol Lett (2015) 0.76
The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med (2016) 0.75
Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. Contemp Oncol (Pozn) (2012) 0.75
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol (2015) 0.75
IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma. Korean J Pathol (2014) 0.75
Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Molecular profiling of small renal masses: Current status and future directions. Indian J Urol (2009) 0.75
IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis. Oncol Lett (2017) 0.75
Prognostic value of high IMP3 expression in solid tumors: a meta-analysis. Onco Targets Ther (2017) 0.75
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
What do we mean by validating a prognostic model? Stat Med (2000) 9.18
Assessing the generalizability of prognostic information. Ann Intern Med (1999) 8.04
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
External validation is necessary in prediction research: a clinical example. J Clin Epidemiol (2003) 3.49
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol (2006) 1.61
A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl (2001) 1.61
Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst (2007) 1.42
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res (2007) 1.30
Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemia. Growth Horm IGF Res (1998) 1.10
Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology (2007) 1.09
Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer (2007) 1.07
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol (2003) 1.04
Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol (2004) 0.99
Renal cell carcinoma with non-islet cell tumor hypoglycemia. Int J Urol (2006) 0.81
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol (2006) 3.05
Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res (2007) 2.77
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res (2005) 2.42
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology (2012) 2.35
Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res (2007) 2.26
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10
Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol (2004) 2.08
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Small bowel obstruction-who needs an operation? A multivariate prediction model. World J Surg (2010) 1.94
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol (2010) 1.93
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology (2009) 1.92
Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc (2012) 1.92
A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem (2008) 1.87
IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res (2008) 1.87
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst (2008) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol (2010) 1.76
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology (2008) 1.76
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71